Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22949 of 23102  at  10/20/2019 10:11:52 AM  by

hbomb57108


 In response to msg 22948 by  rad.onco
view thread

Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Yeah, I believe kol's were not convinced because they didnt consider erlotinib standard of care when study finished. At the time it was said they would follow up with more studies.


Here is OS results from that study.

https://www.cancernetwork.com/lung-cancer/cabozantinib-improves-outcomes-over-erlotinib-advanced-nsclc

Overall survival was also improved with cabozantinib. The cabozantinib monotherapy group had a median overall survival of 9.2 months, compared with 5.1 months with erlotinib (HR, 0.68; 95% CI, 0.49–0.95; P = .071). The combination group had a median overall survival of 13.3 months (HR, 0.51; 95% CI, 0.35–0.74; P = .011). Objective response rates were similar across the groups.

The new study’s authors plan to follow up with a study of cabozantinib involving a non-erlotinib control group, to “further delineate a role for cabozantinib in the treatment of advanced non-squamous NSCLC.”



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 264
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
22950 Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) rad.onco 2 10/20/2019 12:28:20 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...